This week, we’re sharing the most recent top stories in internal medicine news. New data shows that some patients are experiencing delayed rash after taking the Moderna Vaccine. Additionally, new studies show interesting results on patients responding positively to telehealth visits for dermatology visits, with 80.8% of patients stating the overall appointment was satisfactory.
Some Experience Delayed Rash After Moderna Shot, Study Says Bloomberg, March 3, 2021
Some people who get Moderna Inc.’s vaccine experience delayed rashes that can be four inches wide or more and take around six days to resolve, according to a report in the New England Journal of Medicine. They were typically treated with ice and antihistamines, although some patients needed steroid treatments. About half also got skin reactions after the second dose, though they were less severe.
Survey: Most Patients Support Teledermatology Medscape, February 16, 2021
The majority of patients, 55%, at one dermatology clinic agreed that teledermatology "was an adequate substitute for an in-person appointment" and 80% said that they would consider another such visit in the future, according to a survey conducted at George Washington University in Washington.
Poor cardiorespiratory fitness early in life may predict psoriatic disease in men Healio, March 1, 2021
Men with poor cardiorespiratory fitness levels during late adolescence were more likely to develop psoriasis or psoriatic arthritis later in life, according to a study. The analysis included 20,679 cases of incident psoriasis and 6,133 cases of incident psoriatic arthritis observed among 1,228,562 Swedish men.
Asthma risk may be elevated in atopic dermatitis Healio, February 24, 2021
Individuals with atopic dermatitis carried an elevated risk for asthma compared with those who did not have AD, according to a study. The correlation between AD and asthma may be due to shared features of type 2 immunity and elevated IgE levels, according to the researchers. “Asthma is a common comorbidity of AD,” they wrote.
Don't Stop Taltz in Psoriatic Arthritis Don't Stop Taltz in Psoriatic Arthritis MedPage Today, March 10, 2021
Patients with psoriatic arthritis who achieved minimal disease activity on ixekizumab (Taltz) and continued on the drug fared better than patients who withdrew from treatment, an international randomized trial found.